two great announcements, page-6

re: two great announcements 230% tomorrow Directors buying in, showing support for more things to come.......

And another JBE Holdings purchasing 20,000,000

This is good on the back of the announcement

OBJ's proprietary Dermaportation technology has previously been reported to increase transdermal transportation of caffeine by almost 500%. Caffeine is the standard compound for research and evaluation purposes, however OBJ will now focus on medically and commercially important drugs, therapeutic compounds and cosmetic agents. 2 OBJ has already been invited to presents its research findings at 4 major
pharmaceutical, dermatological, cosmetic and scientific conferences, however the company anticipates an elevation in international interest once results start to emerge from the WABRI contract.


OBJ moves to human Clinical Trials OBJ Limited (OBJ) announces that it has signed a clinical trial and drug delivery study contract with the Western Australian Biomedical Research Institute (WABRI).

The contract, which includes the first volunteer human trial into the use of OBJ's Dermaportation technology will commence immediately and run over a 40 week
period.

The 3-part program involves in-vitro studies into the enhanced transdermal (through- the-skin) delivery of 10 and 12 commercially important drugs and local anaesthetics, as well as human clinical trials.

The human trials will invoke an evaluation of OBJ's micro-computer controlled transdermal delivery system to increase the speed of delivery and efficacy of locally
applied anaesthetics.